Clitoria ternatea as a phytopharmacological resource: plant metabolites, mechanistic evidence, translational prospects, and safety considerations
- 1Department of Pharmacognosy, Vignan Institute of Pharmaceutical Technology
- 2Department of Physiology, Bankura Christian College
- 3Department of Pathology, Shri B. M. Patil Medical College Hospital and Research Centre, BLDE (Deemed to be University)
Abstract
Clitoria ternatea L. (Fabaceae; butterfly pea) is used in traditional medicine and is increasingly developed as a food colorant, functional beverage, botanical preparation, and source of peptide scaffolds. Previous reviews have separately emphasized ethnomedicine, flower extraction, anthocyanins, or cyclotides; however, the evidence has rarely been integrated according to preparation identity, study design, bioavailability, safety, and translational readiness. This structured critical narrative review updates the literature through 8 August 2026. PubMed, Scopus, ScienceDirect, and Google Scholar were searched using species-name and domain-specific terms. Primary studies were prioritized, and evidence was stratified as chemical/analytical, in silico , isolated-target or cell-based, animal, and human. Study interpretation considered taxonomic authentication, plant part, extraction and chemical characterization, dose, controls, duration, model relevance, adverse-event reporting, and exposure plausibility. The principal metabolite classes are ternatin anthocyanins, flavonol glycosides, phenolic acids, triterpenoids, sterols, and cyclotides. Chemical assays such as DPPH and ABTS support redox characterization but do not establish pharmacological or therapeutic efficacy. Neurobehavioral, anti-inflammatory, metabolic, antimicrobial, organ-protective, and cytotoxic signals are reported mainly in preclinical models, often using incompletely standardized extracts. Human evidence is restricted to small acute crossover studies and exploratory adjunctive studies, including a 2026 study of flower tea in people with type 2 diabetes and diabetic distress. Intact ternatins are orally absorbed in rats, but systemic exposure is modest and human pharmacokinetic data are unavailable; metabolite exposure, formulation effects, chronic toxicity, reproductive safety, cyclotide immunogenicity, and botanical-drug interactions remain insufficiently defined. Recent genomic and peptide studies strengthen the biotechnology relevance of cyclotides and butelase-1 but should not be conflated with the efficacy of crude botanical preparations. Overall, C. ternatea is a promising source of defined food, botanical, and peptide products, but therapeutic claims require authenticated materials, marker-based standardization, exposure-linked pharmacology, and adequately controlled clinical trials.
Related
- Defining Personalization in Functional Brain Imaging: Conceptual, Methodological, and Translational Considerations
- Neoantigen nanovaccines for cancer immunotherapy: design strategies, translational bottlenecks, and clinical prospects.
- Halophyte-associated salt-tolerant rhizobacteria: ecological adaptation, mechanistic pathways, and translational relevance for wheat salinity tolerance
- Protective effects of icariin in atherosclerotic cardiovascular disease: mechanistic basis, post-ischemic protection and translational limitations
- Molecular Mechanisms, Evidence Levels, and Translational Prospects of Natural Products in Non-Small Cell Lung Cancer: A Critical Narrative Review
BibTeX
@article{devi2026clitoria,
title = {{Clitoria ternatea as a phytopharmacological resource: plant metabolites, mechanistic evidence, translational prospects, and safety considerations}},
author = {Dharmasoth Rama Devi and Salapu Neelima Maheswari and Rajana Krishna Saranya and Surisetty Aashritha and Nooka Gouri Sankar and Nissi Abigail Gurrala and Prithviraj Karak and Sayandeep K. Das},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1922024},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1922024/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Clitoria ternatea as a phytopharmacological resource: plant metabolites, mechanistic evidence, translational prospects, and safety considerations
AU - Dharmasoth Rama Devi
AU - Salapu Neelima Maheswari
AU - Rajana Krishna Saranya
AU - Surisetty Aashritha
AU - Nooka Gouri Sankar
AU - Nissi Abigail Gurrala
AU - Prithviraj Karak
AU - Sayandeep K. Das
PY - 2026
DA - 2026/10/16
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1922024
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1922024/full
AB - Clitoria ternatea L. (Fabaceae; butterfly pea) is used in traditional medicine and is increasingly developed as a food colorant, functional beverage, botanical preparation, and source of peptide scaffolds. Previous reviews have separately emphasized ethnomedicine, flower extraction, anthocyanins, or cyclotides; however, the evidence has rarely been integrated according to preparation identity, study design, bioavailability, safety, and translational readiness. This structured critical narrative review updates the literature through 8 August 2026. PubMed, Scopus, ScienceDirect, and Google Scholar were searched using species-name and domain-specific terms. Primary studies were prioritized, and evidence was stratified as chemical/analytical, in silico , isolated-target or cell-based, animal, and human. Study interpretation considered taxonomic authentication, plant part, extraction and chemical characterization, dose, controls, duration, model relevance, adverse-event reporting, and exposure plausibility. The principal metabolite classes are ternatin anthocyanins, flavonol glycosides, phenolic acids, triterpenoids, sterols, and cyclotides. Chemical assays such as DPPH and ABTS support redox characterization but do not establish pharmacological or therapeutic efficacy. Neurobehavioral, anti-inflammatory, metabolic, antimicrobial, organ-protective, and cytotoxic signals are reported mainly in preclinical models, often using incompletely standardized extracts. Human evidence is restricted to small acute crossover studies and exploratory adjunctive studies, including a 2026 study of flower tea in people with type 2 diabetes and diabetic distress. Intact ternatins are orally absorbed in rats, but systemic exposure is modest and human pharmacokinetic data are unavailable; metabolite exposure, formulation effects, chronic toxicity, reproductive safety, cyclotide immunogenicity, and botanical-drug interactions remain insufficiently defined. Recent genomic and peptide studies strengthen the biotechnology relevance of cyclotides and butelase-1 but should not be conflated with the efficacy of crude botanical preparations. Overall, C. ternatea is a promising source of defined food, botanical, and peptide products, but therapeutic claims require authenticated materials, marker-based standardization, exposure-linked pharmacology, and adequately controlled clinical trials.
SN - 1663-9812
ER -